Shares shifted sharply upward as Hims & Hers Health clawed back losses from last week's FTC lawsuit, trading at $29.58 — up 6.5% — and extending a rally that has now recovered 18.3% from the July 29 intraday low of $25.00. The stock initially fell nearly 15% the day the complaint dropped. The rebound signals investors are recalibrating the severity of the regulatory hit, but the real test arrives Monday: Hims will release Q2 2026 earnings after market close on August 10.

  • The Government Is Attacking the Company's Core Promise. The complaint alleges Hims shared consumers' sensitive health information with advertising platforms including Meta and Snap, despite marketing its services as private and discreet, and that it engaged in deceptive subscription billing and cancellation practices. For a brand that sells medications for weight loss, erectile dysfunction, and hair loss — conditions people want to keep quiet — the FTC alleged Hims placed pixel-sized trackers from Meta, Snap, Microsoft, Pinterest, Reddit, and X that "captured and shared users' health information." Trust is the product here. If customers hesitate to sign up, subscriber growth stalls.

  • Prior Settlements Suggest Manageable Fines, But Harsher Restrictions. In a similar case, GoodRx paid a $1.5 million civil penalty and was barred from sharing health data for advertising.

Cerebral paid a $7 million fine to settle similar tracking-pixel allegations. Those are pocket change for Hims, which sits near a ~$7 billion market cap. The bigger risk is an injunction banning health-data-fueled ad targeting — the very engine that drives its customer acquisition machine.

  • Earnings on Monday Could Overshadow Everything. Analysts expect Hims to post earnings of -$0.049 per share and revenue of $698.9 million for Q2. That revenue figure would mark a significant rebound from last quarter, when the company missed consensus, reporting -$0.40 EPS and $608.1 million in revenue.

Options markets are pricing a 14% move around the report — meaning the FTC noise could get drowned out fast by either a beat or a miss.

  • The Stock Is Still Down 51% Over the Past Year. HIMS has delivered a -55.6% change over the past 12 months, with a 52-week range between $13.74 and $65.59.

FactSet's average analyst rating is Hold, with a mean price target of $30.15 — barely above today's price. The FTC case adds a genuine overhang, but for long-term shareholders the question is simpler: can Hims prove its weight-loss and branded GLP-1 business is growing fast enough to justify paying up through the legal fog?